Last reviewed · How we verify
NCT05486988
ctDNA as a Biomarker for Treatment in Advanced NSCLC
trial testing Immunotherapy in Non-small Cell Lung Cancer in 500 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Fuzhou General Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 31 July 2022 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Immunotherapy — full drug profile →
- Chemotherapeutic Agent — full drug profile →
- Chemotherapy (chemotherapy) — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
Fuzhou General Hospital
Who can join
Adults 18 to 80, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The dynamic monitoring of circulating tumor DNA aims to evaluate the response and progression-free survival of short-course chemotherapy (2 cycles) combined with immunotherapy in patients with locally advanced unresectable or metastatic non-small cell lung cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05486988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunotherapy
Trials testing the same drug.
- NCT07293247 — A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After · Phase 2 · not yet recruiting
- NCT07259473 — Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
- NCT07297030 — SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer · Phase 2 · not yet recruiting
- NCT07231575 — Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC · Phase 2 · not yet recruiting
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Fuzhou General Hospital trials
Trials by the same sponsor.
- NCT06772376 — SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer · not yet recruiting
- NCT06772363 — SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis · not yet recruiting
- NCT06775587 — SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules · not yet recruiting
- NCT06775002 — SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type · not yet recruiting
- NCT06775015 — SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05486988 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuzhou General Hospital
- Last refreshed: 4 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05486988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing